Your session is about to expire
Irbesartan vs Telmisartan
Introduction
For patients with hypertension or diabetic nephropathy, certain drugs that assist in controlling blood pressure and preventing kidney damage can help manage symptoms and slow disease progression. Irbesartan and Telmisartan are two such drugs commonly prescribed for these conditions. Both of these medications belong to the class of angiotensin II receptor blockers (ARBs), which work by relaxing blood vessels so that blood can flow more easily, thereby lowering the patient's blood pressure. However, their specific mechanisms differ slightly. Irbesartan works primarily by blocking the binding of angiotensin II to receptors in many tissues including vascular smooth muscle and adrenal glands, reducing vasoconstriction and aldosterone secretion. On the other hand, Telmisartan blocks a substance in the body that causes blood vessels to tighten thus relaxes and dilates vessels while also reducing fluid volume via its effects on renal tubules.
Irbesartan vs Telmisartan Side By Side
| Attribute | Avapro | Micardis |
|---|---|---|
| Brand Name | Avapro | Micardis |
| Contraindications | Cannot be taken with certain NSAIDs due to risk of reduced effectiveness and potential kidney damage. Not suitable for pregnant women due to risk of injury or death to the developing fetus. | Cannot be taken with certain NSAIDs due to risk of reduced effectiveness and potential kidney damage. Not suitable for pregnant women due to risk of injury or death to the developing fetus. |
| Cost | For brand name: around $100 for 30 tablets of 150 mg. For generic: ranges from $0.10 to $1 per day depending on dose and pharmacy. | For brand name: about $120 for 30 tablets of 40 mg. For generic: ranges from about $0.50 to $2 per day based on typical dosages. |
| Generic Name | Irbesartan | Telmisartan |
| Most Serious Side Effect | Signs of allergic reaction, severe skin reactions, kidney problems, decreased blood cell levels, high potassium level. | Signs of an allergic reaction, rapid weight gain and feelings of being short of breath, light-headedness or fainting, high potassium levels, liver problems. |
| Severe Drug Interactions | NSAIDs can reduce the effectiveness of Irbesartan and might lead to kidney damage. | NSAIDs can reduce the effectiveness of Telmisartan and might lead to kidney damage. |
| Typical Dose | 150 mg/day, can be increased to 300 mg/day. | Starts at 20–40 mg/day, can be increased to 80 mg/day. |
What is Irbesartan?
Irbesartan (commonly known as Avapro) and Telmisartan (often sold under the brand name Micardis) are both part of a class of drugs called angiotensin receptor blockers (ARBs), which revolutionized the treatment of hypertension and heart failure. Irbesartan was first approved by the FDA in 1997, with its primary function being to prevent angiotensin II from binding to receptors on blood vessels, helping them relax and lower blood pressure effectively. It is prescribed for treating high blood pressure and protecting kidneys from damage due to diabetes.
Telmisartan has similar effects but also activates peroxisome proliferator-activated receptor gamma (PPARγ), an important factor involved in energy metabolism. This dual action can provide additional benefits for patients with conditions like metabolic syndrome or type 2 diabetes, where energy metabolism is disrupted. Despite these differences, both drugs have been found to be well-tolerated and effective at lowering blood pressure.
What conditions is Irbesartan approved to treat?
Irbesartan is approved for the treatment of different conditions:
- Hypertension, also known as high blood pressure
- Diabetic nephropathy in patients with type 2 diabetes mellitus and hypertension
- Reduction in the risk of progression to overt nephropathy or death amongst patients with type 2 diabetes mellitus and an elevated serum creatinine
How does Irbesartan help with these illnesses?
Irbesartan is used to manage high blood pressure by blocking the action of angiotensin II, a hormone that constricts blood vessels. It does this by attaching itself to angiotensin receptors in the blood vessels, preventing angiotensin II from exerting its effect. As a result, Irbesartan keeps the blood vessels from narrowing and thereby reduces blood pressure. Angiotensin II also stimulates the release of another hormone called aldosterone which causes salt and water retention in the body. When these two actions are blocked, it lowers an individual's blood pressure and can help prevent heart attacks or strokes.
Telmisartan works similarly but has an additional beneficial effect as it is also considered a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that helps regulate lipid metabolism. This means Telmisartan not only helps lower your high blood pressure but may also improve metabolic parameters like insulin resistance - especially important for patients with diabetes or pre-diabetes.
What is Telmisartan?
Telmisartan, sold under the brand name Micardis among others, is an angiotensin II receptor antagonist (ARB) that helps to reduce high blood pressure by blocking the action of angiotensin, a chemical in your body which causes blood vessels to tighten and narrow. It was first approved by the FDA in 1998.
As Telmisartan does not act as a beta-blocker or calcium channel blocker, it has a different side-effect profile compared to those classes of medications. For example, its lack of action on heart rate means that it is less likely to cause fatigue and sexual dysfunction (common side effects of beta-blockers). Furthermore, Telmisartan's effects are particularly beneficial for patients with hypertension who do not respond well to "typical" antihypertensive drugs such as beta-blockers or calcium channel blockers.
It's important to note that while both Irbesartan and Telmisartan belong to the same class of medication and work similarly in reducing high blood pressure; certain individuals may find one more effective than the other due their individual health status.
What conditions is Telmisartan approved to treat?
Telmisartan has been granted approval by the FDA for the management of:
- Hypertension, also known as high blood pressure
- Cardiovascular risk reduction in patients unable to take ACE inhibitors. It helps prevent strokes, heart attacks and kidney problems in people at high risk due to various cardiovascular conditions.
How does Telmisartan help with these illnesses?
Angiotensin II is a hormone that plays a crucial role in the body's fluid balance and blood pressure regulation. It causes constriction of the blood vessels, secretion of aldosterone (a hormone that increases sodium reabsorption), and stimulation of thirst, all leading to increased blood volume and hence elevated blood pressure. Telmisartan works by blocking angiotensin II receptors in the body, thereby preventing these effects and resulting in lowered blood pressure. Its action on peroxisome proliferator-activated receptor gamma (PPARγ) may also contribute to its antihypertensive effects. Since it does not significantly affect bradykinin levels (unlike ACE inhibitors), it is often prescribed when a patient does not respond well or has side effects with ACE inhibitors such as cough or angioedema (swelling). Compared to other ARBs like irbesartan, telmisartan has longer lasting effects which permits once-daily dosing for better patient compliance.
How effective are both Irbesartan and Telmisartan?
Both Irbesartan and Telmisartan are widely used angiotensin II receptor blockers (ARBs) for the management of hypertension, with their FDA approvals only a year apart. Since they act on the same receptors but have slightly different pharmacological properties, they may be prescribed under specific circumstances. A 2009 double-blind clinical trial directly compared irbesartan and telmisartan in patients with hypertension; both drugs demonstrated similar efficacy in blood pressure control as well as comparable safety profiles.
A review conducted in 2012 indicated that irbesartan is effective at lowering blood pressure from the onset of treatment, has a favorable side effect profile when compared to many other antihypertensive agents, and is generally well-tolerated across diverse patient populations including elderly individuals. The same study reported that irbesartan has become one of the most commonly prescribed ARBs worldwide. Optimal efficacy appears to occur at a dose of 150-300 mg/day, and beyond controlling high blood pressure, it also contributes significantly towards reducing cardiovascular risk associated with uncontrolled hypertension.
A 2016 meta-analysis suggested that telmisartan shows greater potency than placebo in treating hypertension, offering similar effectiveness to other common antihypertensive agents. However, unlike many first-line treatments like ACE inhibitors or calcium channel blockers which are considered before ARBs for essential hypertension treatment due its robust evidence base over decades of use; telmisartan often comes into consideration after these have been tried or if there's need to avoid certain side effects such as dry cough associated with ACE inhibitors. Although data confirming its standalone efficacy is substantial like irbesartan but given each individual’s unique medical history and response to medication can lead doctors sometimes prefer one over another.
Related trials for irbesartan and telmisartan
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Irbesartan typically prescribed?
Oral dosages of Irbesartan for hypertension typically start at 150 mg/day, but studies have shown that a dosage increase to 300 mg/day can provide additional blood pressure control. For kidney disease in patients with hypertension and type-2 diabetes mellitus, the usual dose is 300 mg once daily. Children under the age of 16 should not take this medication. If there's no adequate response or if the blood pressure isn't controlled after several weeks of treatment, other blood pressure medications may be added. The maximum dosage that should not be exceeded in any case is 300 mg/day.
At what dose is Telmisartan typically prescribed?
Telmisartan treatment typically commences with a dosage of 20–40 mg/day. The dosage can then be incremented to 80 mg/day, administered as one dose in the morning. However, if there is no response or inadequate control of blood pressure after several weeks, an additional antihypertensive agent may be added to the therapy regimen instead of increasing Telmisartan's dosage beyond 80mg per day. This approach ensures that hypertension is effectively managed while minimizing potential side effects from high dosages of a single drug.
What are the most common side effects for Irbesartan?
Common side effects of Irbesartan can include:
- Diarrhea
- Heartburn or stomach pain
- Tiredness, fatigue
- Dizziness or lightheadedness due to reduced blood pressure
Whereas common side effects of Telmisartan may encompass:
- Back pain
- Sinusitis (inflammation of the sinus cavities in the head)
- Diarrhea
- Pharyngitis (inflammation in the back of the throat)
Note: Both medications can cause more serious side effects related to kidney problems and a decrease in red and white blood cells. It's important to consult with your healthcare provider if you experience any severe symptoms after taking either medication.
Are there any potential serious side effects for Irbesartan?
While Irbesartan and Telmisartan are similar in their function as angiotensin II receptor blockers, there can be different side effects to watch out for:
- Signs of allergic reaction: hives, difficulty breathing, swelling on your face or throat
- Severe skin reactions: fever, sore throat, burning sensation in the eyes, skin pain followed by a red or purple rash that spreads (especially in the face or upper body) causing blistering and peeling
- Kidney problems: Little to no urination; painful or difficult urination; swelling in your feet or ankles; feeling tired
- Decreased blood cell levels - Fever, chills, dizziness/feeling light-headedness
- High potassium level – Nausea; weakness; tingly feeling; chest pain irregular heartbeats If you experience any of these symptoms while taking either of these medications it is important to consult your healthcare provider immediately.
What are the most common side effects for Telmisartan?
While Telmisartan is also an effective medication for managing hypertension, it comes with its set of potential side effects. These may include:
- Back pain or muscular discomfort
- Sinus congestion, sore throat and stuffy nose
- Fluctuations in blood pressure that can lead to dizziness
- Abdominal discomfort, including stomach pain, nausea or loss of appetite
- Disturbances in sleep patterns leading to insomnia
- Occasional headache
- Possible skin reactions such as rash
- Increased frequency of urination It's important to note that most people don't experience all these symptoms and the extent varies from person to person. Always consult your healthcare professional when starting any new medication.
Are there any potential serious side effects for Telmisartan?
While Telmisartan is generally well-tolerated, it's important to be aware of potential serious side effects. Some symptoms that may require immediate medical attention include:
- Signs of an allergic reaction such as skin rash or hives; swelling of the face, lips, tongue or throat; difficulty breathing
- Rapid weight gain and feelings of being short of breath (these could indicate a kidney problem)
- Light-headedness or fainting - this could suggest low blood pressure
- High potassium levels which can cause nausea, slow or unusual heart rate, weakness or loss of movement
- Signs pointing towards liver problems like upper stomach pain, fatigue and jaundice (yellowing in your skin or eyes)
Should you experience any severe adverse reactions while on Telmisartan treatment immediately seek medical help.
Contraindications for Irbesartan and Telmisartan?
Both Irbesartan and Telmisartan, similar to many other antihypertensive medications, may cause a decrease in blood pressure that's too rapid for some people. If you notice your symptoms worsening, or an increase in lightheadedness, fainting spells, or abnormal heartbeats after taking these drugs, please seek immediate medical attention.
Neither Irbesartan nor Telmisartan can be taken if you are taking certain anti-inflammatory medicines (NSAIDs) since they can reduce the effectiveness of these hypertension drugs and might lead to kidney damage. Always tell your physician which medications you are currently using; NSAIDs will require careful monitoring while being administered alongside either Irbesartan or Telmisartan to prevent dangerous interactions.
Pregnant women should not take either drug due to the risk of injury and even death to the developing fetus. It is important that women of childbearing age use adequate contraception while on this medication.
How much do Irbesartan and Telmisartan cost?
For the brand name versions of these drugs:
- The price of 30 tablets of Avapro (Irbesartan, 150 mg) averages around $100, which works out to approximately $3.33/day.
- The price of 30 tablets of Micardis (Telmisartan, 40 mg) is about $120, working out to roughly $4/day.
Thus, if you are in the higher dosage range for Irbesartan (i.e., up to 300 mg/day), then brand-name Telmisartan becomes less expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which drug is right for you.
For the generic versions of Irbesartan and Telmisartan:
- Generic Irbesartan (150 mg tablets) comes in packs starting from 30 capsules with approximate costs ranging from $0.10 to $1 per day depending on your dose and pharmacy.
- Generic Telmisartan can also be found starting at quantities as low as 15 capsules (40mg each); costs vary widely by location but typically fall between about $0.50 and $2 per day based on typical dosages.
Popularity of Irbesartan and Telmisartan
Irbesartan, in both its generic form and under brand names such as Avapro, was given to approximately 8.2 million people in the USA in 2020. This represented about 10% of all angiotensin receptor blocker (ARB) prescriptions within the country for that year. As an ARB drug, irbesartan is commonly used to treat high blood pressure and kidney disease related to diabetes.
On the other hand, Telmisartan in its generic form or under brands like Micardis accounted for around 5 million prescriptions within the same timeframe. It contributes to roughly 6% of total ARB prescriptions across America; it's also mainly prescribed for hypertension treatment and reducing cardiovascular risk associated with heart diseases.
Both drugs have seen a gradual increase in prescription rates over recent years due largely to their effectiveness at managing long-term health conditions like hypertension without causing significant side effects compared with other drug classes.
Conclusion
Both Irbesartan and Telmisartan are widely used in the treatment of hypertension, and have been proven to be more effective than placebo treatments through numerous clinical studies and meta-analyses. They belong to a class of drugs known as angiotensin II receptor blockers (ARBs), which work by blocking the binding of angiotensin II, thus relaxing blood vessels and lowering blood pressure. While both drugs share similar mechanisms of action, they may be chosen for different patient populations or health conditions due to their unique characteristics.
Telmisartan has an additional property of being a partial agonist at peroxisome proliferator-activated receptors (PPARs), which gives it potential benefits in metabolic disorders like diabetes. Irbesartan, on the other hand, has a high oral bioavailability and is not associated with food interactions making it easier for patients to take anytime during the day.
Both drugs are available as generics representing significant cost savings especially for those who must pay out-of-pocket. Both Irbesartan and Telmisartan might take some time before their full effects can be noticed.
The side effect profile is fairly similar between these two medications; they're generally well-tolerated but do carry risk factors such as dizziness or kidney problems that need monitoring from healthcare professionals. As with all medication changes or initiations, close communication with your doctor is essential when starting either drug regimen.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Derosa, G. (2010, May). Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. Integrated Blood Pressure Control. Informa UK Limited.http://doi.org/10.2147/ibpc.s6081
- Battershill, A. J., & Scott, L. J. (2006). Telmisartan. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-200666010-00004
- Frampton, J. E. (2011, April). Telmisartan. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/11206710-000000000-00000
- Pietrement, C., Malot, L., Santerne, B., Roussel, B., Motte, J., & Morville, P. (2003, April 1). Perinatal/Neonatal Case Presentation: Neonatal Acute Renal Failure Secondary to Maternal Exposure to Telmisartan, Angiotensin II Receptor Antagonist. Journal of Perinatology. Springer Science and Business Media LLC.http://doi.org/10.1038/sj.jp.7210871
- Croom, K. F., Curran, M. P., Goa, K. L., & Perry, C. M. (2004). Irbesartan. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-200464090-00011
- Derosa, G., Fogari, E., D'Angelo, A., Cicero, A. F. G., Salvadeo, S. A. T., Ragonesi, P. D., … Fogari, R. (2007, June). Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics. Hindawi Limited.http://doi.org/10.1111/j.1365-2710.2007.00820.x
- Sasso, F. C., Carbonara, O., Persico, M., Iafusco, D., Salvatore, T., D’Ambrosio, R., … Cozzolino, D. (2002, November 1). Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/diacare.25.11.1909
- Yamagishi, S.-. ichi ., & Nakamura, K. (2006, January 1). Telmisartan, its Potential Therapeutic Implications in Cardiometabolic Disorders. Recent Patents on Cardiovascular Drug Discovery. Bentham Science Publishers Ltd.http://doi.org/10.2174/157489006775244281